Shares surged +10.6% to $131.46 after Incyte delivered a second quarter that blew past Wall Street on almost every metric. But the headline numbers carry a major asterisk: a one-time government settlement that padded results by nearly a quarter-billion dollars. The question for shareholders is whether the underlying business momentum justifies a stock now trading well above every analyst's average price target.
A Massive Beat, Powered Partly by a One-Time Windfall
Total revenue grew 38% to $1.67 billion , and adjusted net income rose to $643.4 million, or $3.09 per share, from $1.57 per share last year . Analysts had expected earnings of $2.15 per share on revenue of $1.49 billion — making the EPS beat roughly 44%. However, the increase was driven by a one-time, non-cash benefit of $246 million associated with the reversal of previously established accrual balances for its eczema and vitiligo cream, Opzelura, following a CMS (Centers for Medicare & Medicaid Services) settlement. Excluding that benefit, total net sales increased 17% year over year — still solid, but far less dramatic.
Opzelura Goes From Disappointment to Star Performer
Opzelura net sales surged 173% to $450 million — a stunning reversal from Q1, when Opzelura sales of $143 million slightly missed analyst expectations . Analysts had forecast only $214.7 million for the quarter . Strip out the CMS windfall and underlying Opzelura demand still grew meaningfully, but investors should recognize the $246 million boost won't repeat.
Raised Guidance Signals Confidence Beyond the Settlement
Incyte raised its full-year net sales guidance to $5.13–$5.26 billion from $4.77–$4.94 billion, and increased its Opzelura forecast to $1.05–$1.10 billion — well above the original $750–$790 million target. Jakafi, the company's largest drug, posted $817 million in Q2 sales, up 7% , and hematology and oncology sales increased 69% to $222 million, with Niktimvo generating $60 million .
A Rich Cash Pile Raises Capital Allocation Questions
Incyte held $4.5 billion in cash and marketable securities as of June 30, up from $3.6 billion at year-end 2025 . That war chest, combined with 10 Phase 3 studies underway , gives management flexibility — but at $131, the stock is trading well above the average analyst price target of $114.87 . The market is pricing in sustained outperformance; any stumble in Opzelura's organic demand curve or pipeline setbacks could quickly reverse today's euphoria.